Tech Company Financing Transactions
Neurogastrx Funding Round
On 1/5/2018, Neurogastrx received $45 million in Series A funding from 5AM Ventures, OrbiMed and venBio.
Transaction Overview
Company Name
Announced On
1/5/2018
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
5AM Ventures (Lead Investor) (David Allison)
OrbiMed (Lead Investor) (Klaus Veitinger)
venBio (Lead Investor) (Aaron Royston)
Proceeds Purpose
The funds will allow the company to fill out the management team and reach proof of concept with its lead asset, NG-101, which is intended to treat gastroparesis, a debilitating functional GI disorder.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
600 Unicorn Park Dr.
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Undisclosed
Website
Email Address
Overview
Neurogastrx, Inc. is a biopharmaceutical company developing products for the treatment of gastrointestinal disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James O'Mara
Chief Scientific Officer
Cyril De Colle
Browse more venture capital transactions:
Prev: 1/5/2018: Quartet venture capital transaction
Next: 1/5/2018: Concord venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs